I
IGC Pharma, Inc.
IGCCIK 0001326205NYSENon-AcceleratedSmaller ReportingPharmaceutical PreparationsMarylandFY ends Dec 31
Period
FY 2025
Revenue
$1.27M
Net Income
$-7.12M
Total Assets
$8.75M
Equity
$6.33M
Shares Out
100.09M
Op. Cash Flow
$-4.79M
Business
IGC Pharma is a biopharmaceutical company developing investigational therapies for Alzheimer's disease and central nervous system disorders. Its lead asset, IGC-AD1, is a cannabinoid-based combination therapy in Phase 2 clinical trials for agitation in Alzheimer's patients. The company operates a preclinical pipeline and conducts clinical research in-house across the U.S., Canada, and Colombia, with incidental over-the-counter wellness products manufactured in Washington state.
Summary from 10-K filed 2025-06-27
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-03-31 | FY 2024 2024-03-31 | FY 2023 2023-03-31 | FY 2022 2022-03-31 | FY 2021 2021-03-31 |
|---|---|---|---|---|---|---|
| Revenue | 1 | 1 | 911,000 | 397,000 | 898,000 | |
| Cost of revenue | −652,000 | −612,000 | −469,000 | −203,000 | −785,000 | |
| Gross profit | 619,000 | 733,000 | 442,000 | 194,000 | 113,000 | |
| Selling, general and administrative expenses | −4 | −7 | −9 | −13 | −8 | |
| Research and development expenses | −4 | −4 | −4 | −2 | −900,000 | |
| Operating loss | −7 | −10 | −12 | −15 | −9 | |
| Impairment loss on PPE | 0 | −3 | 0 | — | — | |
| Other income, net | 325,000 | 143,000 | 65,000 | 461,000 | 82,000 | |
| Loss before income taxes | −7 | −13 | −12 | −15 | −9 | |
| Income tax expense/benefit | 0 | 0 | 0 | 0 | 0 | |
| Net loss attributable to common stockholders | −7 | −13 | −12 | −15 | −9 | |
| Foreign currency translation adjustments | −30,000 | −34,000 | −421,000 | −194,000 | 76,000 | |
| Comprehensive loss | −7 | −13 | −12 | −15 | −9 | |
| Basic and diluted (in Dollars per share) | −0.09 | −0.22 | — | — | — | |
| Basic and diluted (in Dollars per share) | −0.09 | −0.22 | — | — | — | |
| Weighted-average number of shares used in computing loss per share amounts: (in Shares) | 77 | 59 | — | — | — | |
| Weighted-average number of shares used in computing loss per share amounts: (in Shares) | 77 | 59 | — | — | — |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-03-31 | FY 2024 2024-03-31 | FY 2023 2023-03-31 | FY 2022 2022-03-31 | FY 2021 2021-03-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 405,000 | 1 | 3 | 10 | 15 | |
| Accounts receivable, net | 34,000 | 39,000 | 107,000 | 125,000 | 175,000 | |
| Inventory | 1 | 2 | 3 | 4 | 5 | |
| Asset held for sale | 702,000 | 720,000 | 0 | — | — | |
| Deposits and advances | 395,000 | 208,000 | 358,000 | 978,000 | 3 | |
| Total current assets | 3 | 4 | 6 | 15 | 24 | |
| Intangible assets, net | 2 | 2 | 1 | 917,000 | 407,000 | |
| Property, plant and equipment, net | 3 | 4 | 8 | 9 | 11 | |
| Claims and advances | 681,000 | 688,000 | 1 | 937,000 | 603,000 | |
| Operating lease asset | 98,000 | 198,000 | 326,000 | 450,000 | 488,000 | |
| Total non-current assets | 6 | 6 | 11 | 12 | 12 | |
| Total assets | 9 | 10 | 17 | 27 | 36 | |
| Accounts payable | 883,000 | 773,000 | 530,000 | 981,000 | 476,000 | |
| Accrued liabilities and others | 1 | 2 | 1 | — | — | |
| Total current liabilities | 2 | 2 | 2 | 2 | 2 | |
| Long-term loans | 134,000 | 137,000 | 141,000 | 144,000 | 276,000 | |
| Other liabilities | 16,000 | 20,000 | 21,000 | 16,000 | 15,000 | |
| Operating lease liability | 10,000 | 84,000 | 207,000 | 341,000 | 405,000 | |
| Total non-current liabilities | 160,000 | 241,000 | 369,000 | 501,000 | 696,000 | |
| Total liabilities | 2 | 3 | 2 | 3 | 3 | |
| Commitments and Contingencies See Note 12 | 0 | 0 | 0 | — | — | |
| Preferred stock, $0.0001 par value: authorized 1,000,000 shares, no shares issued or outstanding as of March 31, 2025, or March 31, 2024. | 0 | 0 | 0 | 0 | 0 | |
| Common stock and additional paid-in capital, $0.0001 par value: 150,000,000 shares authorized; 80,878,058 and 66,691,195 shares issued and outstanding as of March 31, 2025, and March 31, 2024, respectively. | 131 | 124 | 119 | 116 | 110 | |
| Accumulated other comprehensive loss | −3 | −3 | −3 | −3 | −3 | |
| Accumulated deficit | −121 | −114 | −101 | −89 | −74 | |
| Total stockholders equity | 6 | 7 | 15 | 24 | 33 | |
| Total liabilities and stockholders equity | 9 | 10 | 17 | 27 | 36 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-03-31 | FY 2024 2024-03-31 | FY 2023 2023-03-31 | FY 2022 2022-03-31 | FY 2021 2021-03-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 618,000 | 637,000 | 657,000 | 651,000 | 478,000 | |
| Provision for bad debt | 13,000 | 93,000 | 126,000 | 2 | 0 | |
| Impairment of assets | 152,000 | 3 | 0 | 833,000 | 0 | |
| Common stock-based compensation and expenses, net | 2 | 2 | 3 | 2 | 658,000 | |
| Profit/Loss on sale of fixed assets, net | −25,000 | −44,000 | 39,000 | 0 | — | |
| Accounts receivables, net | −8,000 | −25,000 | 5,000 | 50,000 | −42,000 | |
| Inventory | 180,000 | 1 | 897,000 | 2 | −1 | |
| Deposits and advances | −187,000 | 150,000 | 591,000 | 541,000 | −2 | |
| Claims and advances | 7,000 | 315,000 | −150,000 | −334,000 | 93,000 | |
| Accounts payable | 106,000 | 243,000 | −451,000 | 504,000 | −287,000 | |
| Accrued and other liabilities | −196,000 | 197,000 | −88,000 | — | — | |
| Operating lease asset | 100,000 | 129,000 | — | — | 93,000 | |
| Operating lease liability | −74,000 | −123,000 | −134,000 | −64,000 | 0 | |
| Net cash used in operating activities | −5 | −5 | −7 | −7 | −11 | |
| Purchase of property, plant, and equipment | −112,000 | −138,000 | −310,000 | −236,000 | −1 | |
| Sale of property, plant, and equipment | 40,000 | 44,000 | 538,000 | 29,000 | 47,000 | |
| Proceeds from short-term investments | 0 | 154,000 | −154,000 | — | — | |
| Acquisition and development of intangible assets | −370,000 | −377,000 | −309,000 | −535,000 | −122,000 | |
| Net cash used in investing activities | −442,000 | −317,000 | −235,000 | −742,000 | 3 | |
| Net proceeds from the issuance of common stock | 4 | 3 | 103,000 | — | 14 | |
| Proceeds from common stock subscribed | 0 | 500,000 | 0 | — | — | |
| Repayment of long-term loan | −3,000 | −3,000 | −3,000 | −3,000 | 530,000 | |
| Net cash provided by financing activities | 4 | 4 | 100,000 | 4 | 15 | |
| Effects of exchange rate changes on cash and cash equivalents | −7,000 | −6,000 | −82,000 | −26,000 | 15,000 | |
| Net decrease in cash and cash equivalents | −793,000 | −2 | −7 | −4 | 7 | |
| Common stock issued/granted for stock-based compensation, including patent acquisition | 2 | 2 | 3 | 2 | 808,000 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is IGC Pharma, Inc.'s CIK number?
IGC Pharma, Inc.'s SEC CIK number is 0001326205 (1326205). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find IGC Pharma, Inc.'s SEC filings?
All of IGC Pharma, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.